Another interesting agent may be the activin inhibitor luspatercept, which is able to restore late-stage erythropoiesis and to induce hematologic improvement in anemic patients with ineffective erythropoiesis (thalassemia and MDS). Here, INHBE is linked to myelodysplastic syndrome.